Telix Pharmaceuticals (ASX:TLX) reported strong commercial and operational performance for the quarter ended Dec. 31, 2025, achieving its upgraded full-year FY25 revenue guidance with unaudited group revenue of approximately US$804 million.
Fourth-quarter revenue reached about US$208 million, representing 46% year-on-year growth and reflecting accelerating momentum across the business.
Precision Medicine revenue rose to approximately US$161 million, up 4% quarter-on-quarter, driven primarily by the successful US launch of Gozellix following reimbursement approval from the Centers for Medicare and Medicaid Services effective October 2025.
The company said the two-product PSMA strategy, encompassing Illuccix and Gozellix, supported gains in market share and pricing, with revenue growth exceeding dose volume growth.